There are currently 45 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Amyotrophic Lateral Sclerosis participants are California, Florida, Pennsylvania and New York.
Phenotype, Genotype and Biomarkers 2
NCT04875416
Recruiting
The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, the investigator wants to identify the links that exist between the disease phenotype (phenotype refers to observable signs and symptoms) and the disease genotype (genoty... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
05/30/2025
Locations: University of Miami, Miami, Florida +3 locations
Conditions: Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Register for Updates
Clinical Procedures to Support Research in ALS
NCT03489278
Recruiting
The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of California, Irvine, Irvine, California +10 locations
Conditions: Amyotrophic Lateral Sclerosis, ALS-Frontotemporal Dementia, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Register for Updates
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
NCT04097158
Recruiting
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There i... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Loma Linda University, Loma Linda, California
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Analysis of Human ALS Tissues and Registry of ALS Patients
NCT05067179
Recruiting
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a n... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/12/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
NCT06656702
Recruiting
This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
NCT04057898
Recruiting
A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/05/2025
Locations: University of California, Orange, California +15 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
PREVENT ALL ALS Study
NCT06581861
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +31 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
ASSESS ALL ALS Study
NCT06578195
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +31 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Spinal Cord Associative Plasticity for ALS
NCT06172621
Recruiting
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen weakened nerve circuits between the brain and hand muscles in people with ALS. The current proposal will take the next step of individualizing this intervention, then applying it repetitively in an attempt to achieve direct clinical benefit on hand strength and functio... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
EIM Via the Myolex MScan As an ALS Biomarker
NCT06491732
Recruiting
Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
ALS Research Collaborative
NCT06885918
Recruiting
The goal of this natural history study is to learn more about the biological and clinical aspects of amyotrophic lateral sclerosis (ALS). This study's findings will help with drug discovery, biomarker discovery, and outcome measure validation. Adults living with ALS, other motor neuron diseases (MND), a known mutation related to ALS and healthy volunteers contribute prospective and retrospective data to this study remotely. The study is sponsored and conducted by the ALS Therapy Development Inst... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: ALS Therapy Development Institute, Watertown, Massachusetts
Conditions: Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS with Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Register for Updates
Precise Robotically IMplanted Brain-Computer InterfacE
NCT06429735
Recruiting
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant connected to electrode threads that are implanted in the brain by the R1 Robot, a robotic electrode thread inserter.
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/10/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +1 locations
Conditions: Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Quadriplegia/Tetraplegia, Tetraplegic; Paralysis
Register for Updates